Nevertheless, given the clinical failure of PLK1 inhibition in the treatment of HCC, the development of small molecular inhibitors of SETD3 might be a promising strategy to inhibit PLK1 expression for the effective treatment of HCC. The gene discussed is PLK1; the disease is hepatocellular carcinoma.